FindTrial
Sign In

Kedrion IVIG 10%

BIOLOGICAL5 trials

Sponsors

Kedrion S.p.A.

Conditions

AgammaglobulinemiaAntibody DeficiencyChronic Primary Immune Thrombocytopenia (ITP)HypogammaglobulinemiaPrimary ImmunodeficiencyPrimary Immunodeficiency DiseaseStiff Person Syndrome

Phase 3

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
CompletedNCT01581593
Kedrion S.p.A.Agammaglobulinemia, Antibody Deficiency, Hypogammaglobulinemia +1
Start: 2012-11-12End: 2014-08-27Updated: 2021-02-16
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients
CompletedNCT03961009
Kedrion S.p.A.Primary Immunodeficiency Disease
Start: 2019-04-30End: 2020-12-21Updated: 2026-05-05
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
Active, not recruitingNCT04944979
Kedrion S.p.A.Primary Immunodeficiency Disease
Start: 2021-03-31End: 2027-05-01Target: 30Updated: 2026-05-29
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
RecruitingNCT07059000
Kedrion S.p.A.Chronic Primary Immune Thrombocytopenia (ITP)
Start: 2025-08-13End: 2027-01-01Target: 40Updated: 2026-09-11
A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome
Not yet recruitingNCT07552987
Kedrion S.p.A.Stiff Person Syndrome
Start: 2026-09-01End: 2028-07-01Target: 38Updated: 2026-09-14

Related Papers

Clinical Evaluation of Pharmacokinetics, Efficacy, and Safety of a 10% Immunoglobulin in Primary Immunodeficiency Disease (CARES10 Study)
Advances in Therapy2026-05-09
Safety and Tolerability of a New Intravenous Immunoglobulin (IVIg) 10% (KIg10) in Primary Immunodeficiency (PI) Adult Patients
Journal of Human Immunity2025-04-25
Pharmacokinetics of a New Intravenous Immunoglobulin (IVIg) 10% (KIg10) in Primary Immunodeficiency (PI) Patients
Journal of Human Immunity2025-04-25